Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Denali Therapeutics (DNLI)	2.3728 of 5 stars	$18.97	+2.4%	N/A	-19.56	Buy	$50.00
Ultragenyx Pharmaceutical (RARE)	2.5867 of 5 stars	$40.16	+3.4%	N/A	-4.48	Buy	$91.30
Sarepta Therapeutics (SRPT)	2.8998 of 5 stars	$84.44	+3.9%	N/A	-10.78	Moderate Buy	$153.10
Pfizer (PFE)	3.5124 of 5 stars	$28.91	-5.1%	5.67%	15.80	Hold	$42.50
Exelixis (EXEL)	2.8249 of 5 stars	$21.94	+0.6%	N/A	78.36	Moderate Buy	$25.44
Moderna (MRNA)	2.3103 of 5 stars	$79.83	+2.7%	N/A	-8.54	Hold	$133.70
United Therapeutics (UTHR)	2.5956 of 5 stars	$240.73	+0.3%	N/A	13.26	Moderate Buy	$288.00
Biogen (BIIB)	2.8605 of 5 stars	$234.64	+0.2%	N/A	23.32	Moderate Buy	$323.00
Sanofi (SNY)	2.5862 of 5 stars	$46.72	-0.1%	2.95%	14.65	Moderate Buy	$60.00
Eli Lilly and Company (LLY)	2.5338 of 5 stars	$584.04	-1.2%	0.77%	105.80	Moderate Buy	$559.08